Other languages Silo Pharma, Inc.

Equities

SILO

US82711P2011

Delayed Nasdaq Other stock markets 07:33:13 18/06/2024 pm IST			5-day change	1st Jan Change
1.056 ^USD	+0.61%		-8.85%	-28.47%

11/06	Silo Pharma, Inc. announced that it has received $2.077409 million in funding	CI
07/06	Silo Pharma Close to Achieving Optimal Formulation for Ketamine Implant	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Silo Pharma Close to Achieving Optimal Formulation for Ketamine Implant	07/06
Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia	07/06
Top Midday Decliners	05/06
Sector Update: Health Care Stocks Rise Tuesday Afternoon	04/06
Silo Pharma Submits Pre-Investigational NDA For PTSD, Anxiety Treatment; Shares Rise	04/06
Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety	04/06
Silo Pharma, Inc. Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention	21/05
Silo Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment	23/04
Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University	10/04
Silo Pharma, Inc.'s Equity Buyback Plan Extended till March 31, 2024.	04/04
Silo Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Silo Pharma, Inc. Exercises Option for Exclusive License Agreement for First-In-Class PTSD and Stress-Induced Anxiety Therapeutic	20/03
Silo Pharma, Inc. Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain	18/03
Silo Pharma?s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery	14/02
Silo Pharma, Inc. Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology	01/02
Silo Pharma Announces Positive Results in Alzheimer?s Disease Study	24/01
Silo Pharma, Inc.'s Equity Buyback Plan Extended till March 31, 2024.	09/01
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD	04/01
Silo Pharma, Partner Receive Regulatory Approval to Develop Ketamine Implant for Fibromyalgia Treatment	28/12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Silo Pharma, Inc.

Equities

SILO

US82711P2011

Other languages

Filters